1   **Article Summary Line:** Emerging *Plasmodium vivax* infections detected in 10% of febrile

2   malaria patients and 5% of asymptomatic individuals in Duffy-negative populations in

3   Cameroon challenge conventional malaria resistance paradigms, highlighting the need for

4   enhanced surveillance and revised control strategies in Africa.

5   **Running Title:** Epidemiology of *vivax* malaria in Central Africa

6   **Keywords:** Malaria; *Plasmodium vivax*; *Plasmodium falciparum,* Duffy binding protein*,*
7   *PvDBP1,* Cameroon

8

9   **Conventional Malaria Diagnostics Vastly Undermine *Plasmodium vivax* Infections in**

10   **Predominantly Duffy-Negative Africa.**

11   **Authors:** Cheikh Cambel Dieng*, Rene Teh Ning, Canelle Longo Kipayko, Regan Schroeder,

12   Nontokozo Mdluli-Berndt, Bate Ayukenchengamba, Sona Doris, Zidedine Nematchoua, Irene

13   Sumbele Ngole Ule, Helen Kuokuo Kimbi, Eugenia Lo

14

15   **Affiliations:**

16   Drexel University College of Medicine, Philadelphia, Pennsylvania, USA (C. Dieng, C.

17   Kipayko, R. Schroeder, N. Mdluli-Berndt, E. Lo)

18   University of Buea, Buea, Cameroon (R.Teh Ning, B. Ayukenchengamba, S. Doris, Z.

19   Nematchoua, I. Sumbele Ngole Ule, H. Kuokuo Kimbi)

20   University of Bamenda, Bamenda, Bambili, Cameroon (H. Kuokuo Kimbi)

Abstract

Malaria remains a major public health concern in sub-Saharan Africa, and *P. vivax* is emerging in regions with predominantly Duffy-negative populations. This study investigated *P. vivax* prevalence and genetic diversity across three ecological zones in Cameroon. *P. vivax* was detected in ~11% of febrile patients and 5.5% of asymptomatic individuals, all Duffy-negative. Clinical infections exhibited higher parasitemia than community cases. Standard PvLDH-based RDTs produced false-negative results, even at high parasitemia levels, whereas molecular tools like qPCR demonstrated superior sensitivity, particularly for low-density or mixed infections. Genetic analysis of *PvDBP1* identified two prevalent mutations, I379L (73%) and E225K (61%), suggesting adaptive evolution. Phylogenetic analysis clustered Cameroonian isolates with those from Botswana, distinct from Ethiopian and Sudanese strains, indicating historical migration and local adaptation. The detection of asymptomatic *P. vivax* cases highlights the potential for silent transmission, reinforcing the need for enhanced surveillance in both community and clinical settings.

Introduction

Malaria remains a significant global health challenge in sub-Saharan Africa. For decades, *Plasmodium vivax* (*Pv*) was thought to be rare in African populations that lack the Duffy blood group antigen expression[1, 2]. However, recent studies report several *Pv* cases in Duffy-negative people across Africa. The endemic range of *Pv* has extended beyond the Horn of Africa and penetrated areas of very high (>95%) Duffy-negativity. In sub-Saharan Africa, malaria

prevalence varies significantly by region and season. For instance, in Cameroon, the highest

prevalence occurs in the western and northern regions that are mostly highlands(3). The western

region also has higher rainfall, especially in June, which contributes to increased malaria

transmission. While *P. falciparum* (*Pf*) is the major parasite species, *Pv* cases were previously

reported, some of which were non-Cameroonians who resided in Cameroon and later diagnosed

after returning to their home countries(4, 5). In addition, several "*Pv*-like" asymptomatic

infections were identified in schoolchildren on the eastern slope of Mount Cameroon in the

Southwest Region, and these infections were detected solely by microscopy. Two recent studies

also reported an infection rate of 5.6%(6) and 35%(7) of *Pv* in febrile Duffy-negative individuals

in Dschang, northwestern Cameroon by PCR. Nevertheless, these studies were mostly case

reports without characterizing the epidemiological features of *Pv*. Also, the extent of genetic

polymorphisms of the Duffy Binding Protein (DBP) gene, a key gene that the parasites use to

invade human erythrocytes via DARC(8), is unclear among *Pv* from Duffy-negative populations

in Central Africa. Such variations in the African *Pv* relative to other geographical isolates have

important implications in the adaptability and spread of *Pv* across Africa.

Different environmental conditions including temperature, rainfall, and elevation can

impact the abundance and behavior of vector mosquitoes and the parasite's development cycle.

Across the diverse landscape of Cameroon, environmental factors may play a crucial role in

shaping the epidemiological patterns of *Pv*(9). In this study, we compared the prevalence of *Pv*

among the northwest, southwest, and eastern regions of Cameroon in both community and

hospital settings. We further examined genetic polymorphisms of *Pv* from these regions and

compared them to other geographical isolates including those from East Africa and outside

Africa, with the goal to determine genetic diversity and potential evolutionary pathways of the

parasites. The epidemiological and genetic characteristics of *Pv* in African populations,

particularly in Duffy-negative individuals, are essential information for guiding effective control

strategies against this emerging disease across Africa.

Methods

Ethical Statement

The study protocol was approved by the Institutional Review Boards of the Universities

of Buea and Bamenda (Ref No. 2024/2110-06/UB/SG/IRB/FHS). Informed consent was

obtained from all participants or their legal guardians. All methods were carried out in

accordance with relevant guidelines and regulations.

Study Sites and Sample Collection

A cross-sectional study was conducted across three study sites in Cameroon: Bamenda,

Buea, and Bertoua. These sites were selected based on their distinct climatic and landscape

features. Bamenda is situated in a highland region (1201–1400 m). Buea, located 530 meters

above sea level, is a multi-ethnic semi-urban setting where malaria transmission occurs all year-

round(10, 11). Bertoua, located in the Eastern region, is known for its wet equatorial climate and

economic activities in timber and mining(9). A total of 1,373 samples were collected between

April and August 2023, including 793 malaria-suspected patients from hospitals and health

facilities, and 580 from community-based households. Among them, 408 samples were from

Buea, 498 from Bamenda, and 467 from Bertoua; 555 were males and 818 were females. For

each individual, 30–50 μL of finger-pricked blood was preserved on Whatman 3MM filter

papers, air-dried and stored in sealed plastic bags until DNA extraction. Thick and thin blood

smears were prepared for microscopy.

***Plasmodium* Screening, Duffy Genotyping, and *PvDBP1* Sequencing**

Plasmodium species were initially determined using rapid diagnostic tests (RDTs; Bioline

Malaria Ag Pf/Pv manufactured by Abbott Inc) specific to *Pf* (PfHRP2) and *Pv* (PvLDH), as

well as microscopy. Molecular assays were conducted for further diagnosis. Parasitic DNA was

extracted from dried blood spots using a modified Chelex®-saponin method(12, 13) . PCR

amplification targeting the 18S rRNA gene was performed with quantitative PCR(14) to

differentiate between mono-*Pv* and mixed *Pv-Pf* infections. Parasitemia was quantified using the

SYBR Green detection method, following established protocols using *Pv*-specific primers for

18S rRNA gene amplification (Supplementary File 1)(13). Each run included positive controls

from *Pv* Pakchong (MRA-342G) and Nicaragua (MRA-340G) isolates, along with negative

controls. A standard curve was generated based on a ten-fold serial dilution of a *Pv* control

plasmid to assess amplification efficiency (E). Specificity of the amplification was verified by

melting curve analysis. For each sample, the mean cycle threshold (Ct) value and standard error

were calculated from three independent runs. Parasitemia was determined using the equation:

$2^{\wedge}E \times (40-Ct_{sample})$.

106   To further confirm *Pv* infection, we amplified the *PvDBP1* gene region II using *Pv-*

107 specific primers following the published protocol(15). PCR products were purified before Sanger

108 sequencing. To identify the host Duffy blood group, we employed qPCR-based TaqMan assay to

109 examine the point mutation (c.1–67T>C; rs2814778) of the *DARC* gene(16) . A no-template

110 control was used in each assay. The *Fy* genotypes were determined by the allelic discrimination

111 plot based on the fluorescent signal emitted from the allele-specific probes. A 1,100-bp fragment

112 of the *DARC* gene was further amplified using published primers(17) .

114 **Data analysis**

115   To assess factors associated with mono-*Pv* and mixed *Pv-Pf* infections, odds ratios (OR)

116 and 95% confidence intervals (CI) were calculated for various demographic, clinical, and

117 epidemiological variables. The analysis included gender (male vs. female), age (<5 years, 5–15

118 years, and >15 years), and collection origin (community vs. hospital-based) to identify potential

119 risk factors for infection. Symptom-based associations were analyzed to evaluate whether

120 clinical presentation differed between infections caused by mono-*Pv* or mixed infections. The

121 odds ratio was used to estimate the relative risk of infection in different groups using MedCalc

122 statistical software.

123   *PvDBP1* sequences were first aligned using MUSCLE alignment tool to the P01

124 reference strain in Geneious vX.1. The prevalence of observed codon mutations was examined

125 among the Cameroonian *Pv* and compared with other isolates in Thailand and China (Asia),

126 Brazil (South America), Sudan and Ethiopia (East Africa), and Botswana (Southern Africa) that

represent geographically and epidemiologically diverse regions (Figure 4B). Phylogenetic trees

were then constructed using Maximum Likelihood (ML) method in RAxML. The ML tree was

generated with 1,000 bootstrap replicates for statistical support. The General Time Reversible

(GTR) model with gamma distribution was used to account for rate heterogeneity among sites.

The resulting tree was imported into FigTree v1.4.4 for visualization. Sequences are available on

GenBank submission number 2920113.

Results

Prevalence of *Pv* Infections among Duffy-Negatives

The prevalence of mono-*Pv* and mixed *Pv-Pf* infections showed significant variation across the

study sites (Figure 1).

Figure 1. Study sites across Cameroon (Bamenda, Buea, and Bertoua) by hospital and community-based collection and infection type including mono-*P. vivax*, mono-*P. falciparum*, mixed *P. vivax* and *P. falciparum*, and negative samples. The prevalence of mono-*P. vivax* and mixed *P. vivax-P. falciparum* infections showed significant variation across the study sites.

Among 793 hospital samples, the overall prevalence of mono-*Pv* was 11% (*n*=86),

mono-*Pf* was 24.5% (*n*=192), and mixed infections was 13.5% (*n*=106; Figure 2A and Table 1).

All *Pv* infections were Duffy-negative (CC) based on TaqMan genotyping assays. The highest

prevalence of mono-*Pv* and mixed infections was observed in females over 15 years old in

Bamenda (6% and 3.8%, respectively).

Table 1. Prevalence of Mono-*Plasmodium vivax*, Mono-*Plasmodium falciparum*, and mixed
infections across different sex and age groups in Bamenda, Bertoua and Buea. This table
summarizes the infection prevalence of Mono-*Plasmodium vivax* (Mono-Pv), Mono-*Plasmodium*
falciparum (Mono-Pf), and Mixed Infections across three sites in Cameroon (Bamenda, Bertoua,
and Buea). Data are stratified by sex and age groups (>15 years, <5 years, 5-15 years). For each
site, the total number of cases and the percentage distribution of infections are provided. Chi-
square tests were conducted to assess the association between infection type (Mono-Pv, Mono-
Pf, Mixed) and demographic variables (age group, sex). Significant differences were observed in
infection prevalence among different age groups, with higher mixed infection rates observed in
females, especially children under 5, indicating a greater vulnerability to mixed infections (p-
value < 0.05). Specifically, the highest prevalence of mixed infections was observed in Bamenda
(36.54%), followed by Bertoua (34.26%) and Buea (29.20%).

Origin	Site	Sex	Age	Mono-*P.v*	Mono-*P.f*	Mixed Infection	*P.v, P.f* negative	Total
			>15	6.0% (30)	3.2% (16)	3.8% (19)	27.3% (136)	40.4% (201)
		Female	<5	1.4% (7)	4.4% (22)	3.8% (19)	9.8% (49)	19.5% (97)
			5-15	0.4% (2)	1.0% (5)	0	1.0% (5)	2.4% (12)
	Bamenda		>15	1.2% (6)	1.2% (6)	0.6% (3)	8.6% (43)	11.7% (58)
Hospital		Male	<5	1.6% (8)	3.4% (17)	2.4% (12)	16.1% (80)	23.5% (117)
			5-15	0.2% (1)	0	0.2% (1)	2.2% (11)	2.6% (13)
	Buea	Female	>15	5.6% (16)	18.2% (52)	6.7% (19)	15.1% (43)	45.6% (130)

			<5	0.7% (2)	5.6% (16)	1.1% (3)	2.8% (8)	6.7% (29)
			5-15	0.4% (1)	2.8% (8)	2.5% (7)	2.8% (8)	8.5% (24)
			>15	2.8% (8)	7.7% (22)	4.2% (12)	4.2% (12)	18.9% (54)
		Male	<5	1.1% (3)	5.6% (16)	1.8% (5)	2.8% (8)	11.2% (32)
			5-15	0.7% (2)	4.2% (12)	2.1% (6)	2.1% (6)	9.1% (26)
	Total (%)			10.9% (86)	24.5% (192)	13.5% (106)	52.2% (409)	100% (793)
			>15	0.6% (3)	7.5% (35)	1.9% (9)	11.3% (53)	21.4% (100)
		Female	<5	0.2% (1)	5.1% (24)	0.2% (2)	6.4% (30)	12.2% (57)
	Bertoua		5-15	0.9% (4)	11.3% (53)	0.21% (6)	7.9% (37)	21.4% (100)
			>15	0.2% (1)	3.4% (16)	0.6% (3)	4.3% (20)	8.6% (40)
		Male	<5	0.4% (2)	7.1% (33)	0.9% (4)	5.1% (24)	13.5% (63)
			5-15	0.21% (6)	9.9% (46)	1.7% (8)	10.1% (47)	22.9% (107)
			>15	6.2% (7)	8.8% (10)	6.2% (7)	38.9% (44)	60.2% (68)
Community		Female	<5	0	0	0	0	0
	Buea		5-15	0	0	0	0	0
			>15	6.2% (7)	10.6% (12)	2.7% (3)	19.5% (22)	38.9% (44)
		Male	<5	0.9% (1)	0	0	0	0.9% (1)
			5-15	0	0	0	0	0
	Total (%)			5.5% (32)	39.5% (229)	7.2% (42)	47.8% (277)	100% (580)

Among 580 community samples, the overall prevalence of mono-*Pv* was 5.52% (*n*=32),

mono-*Pf* was 39.48% (*n*=229), and mixed infections was 7.24% (*n*=42; Figure 2A and Table 1).

There were no significant differences in *Pv* infection rates between females (8.9%) and males

(8.1%, OR=1.11, *p*=0.597). Similarly, mixed infections were found in 10.3% of males and

11.1% of females, with no significant difference between gender (OR=1.09, *p*=0.617). No

significant difference was observed in parasitemia between mono-*Pv* and mixed *Pv-Pf* infections

(Figure 2B), between females and males, as well as among age groups (Appendix Figure 1;

Appendix Figure 2).

Figure 2. Comparison of *P. vivax* and *P. falciparum* Infections Across Hospital and Community Settings and Parasitemia Levels in Mono and Mixed Infections. (**A**) Panel shows the number of cases for *P. vivax* (*P*.v), and mixed *P. vivax* and *P.* falciparum (*P*.v & *P*.f) infections across hospital (orange bars) and community (olive green bars) settings. Among the hospital samples, 10% (86) were positive for *P. vivax* while 52.3% (409) samples showed mixed

infections, with both *P. vivax* and *P. falciparum* present. In community samples, 5.5% (32) were positive for *P.* vivax and 747.8% (277) samples showed mixed infections. (**B**) Comparison of *P. vivax* parasitemia by qPCR levels between *P.vivax* mono-infections and mixed *P. vivax* infections. No significant difference in parasitemia levels was observed between the two groups, indicating similar parasite burdens in both mono and mixed infections.

Of 119 18S-based qPCR *Pv*-positive samples, 112 (94%) were confirmed by *PvDBP*1-based PCR. However, all qPCR-positive samples were negative by microscopy (Table 2), and only 15 of them (12.6%) were positive by RDTs. These RDT-positive samples showed relatively low Ct values (i.e., high parasite DNA copies) by qPCR (Table 2). While the average parasitemia was higher in the clinical than community *Pv* infections ($p<0.001$; Figure 3), several community-based (asymptomatic at the time of collection) infections were shown with relatively high parasitemia. Specifically, 13% of community samples was within the high parasitemia range (i.e., >1,000 parasites/µL), compared to 21% of hospital cases.

Table 2. Detection of *Plasmodium vivax* Infections across Hospital- and Community-Based Samples. This table shows the *P. vivax* detection using 18S-qPCR, *PvDBP1*-targeted PCR (DBP-PCR), microscopy, and rapid diagnostic tests (RDTs) in hospital-based (N = 793) and community-based (N = 580) samples. Most infections, particularly those with higher Ct values (indicative of lower parasite densities), were undetectable by microscopy and RDT. All qPCR-positive *P. vivax* samples were from Duffy negative individuals.

Hospital-based samples (total *N*= 793)

Ct range by qPCR	18S-qPCR	DBP-PCR+	Microscopic+	RDT+
<20	0	0	0	0
20 - <25	5	5	0	5
25 - <30	17	17	0	7

	30 - <35	20	18	0	0
	>35 - <38	45	43	0	0

Community-based samples (total *N*= 580)

	<20	3	3	0	3
	20 - <25	3	2	0	0
	25 - <30	1	1	0	0
	30 - <35	4	4	0	0
	>35 - <38	21	19	0	0

Figure 3. Comparative Analysis of Parasitemia Levels by Sample Origin in *P. vivax* Infections. Compares parasitemia levels between hospital and community samples, showing significantly higher parasitemia in hospital samples.

Association Between Age, Infection Type, and Symptoms

Age-stratified analysis revealed significant trends in malaria prevalence. Individuals aged 5–15 years had a significantly lower risk of *Pv* infection compared to children under 5 years (OR=0.67, *p*=0.01). It is not surprising that *Pv* was more common in hospital-based participants (10.8%) than those from the community (5.5%), though this difference was not statistically significant (OR=1.16, *p*=0.162). Likewise, mixed infections were also more common in hospital (13.3%) than community samples (7.2%), with a significant two-fold increased risk (OR=2.04, *p*<0.001). Mono-*Pv* infections were not significantly associated with any reported symptoms (fever, nausea, diarrhea, difficulty breathing, muscle pain, or chills); and headache was the only symptom significantly associated with *Pf* infections (OR=3.33, *p*=0.004; Table 3).

Table 3. Demographic, Geographic, and Symptom-Based Risk Factors Associated with *Plasmodium vivax*, *Plasmodium falciparum*, and Mixed Infections. This table presents the distribution of malaria infections across various demographic, geographic, and clinical symptom categories. Significant associations (**p < 0.05**) were observed for several risk factors. Individuals aged **5–15 years** had a significantly **lower risk of *P. vivax* infection**, while those **older than 15 years** had a **higher risk of *P. falciparum* infection**. Hospital-based samples had a **higher prevalence of mixed infections** and a **lower prevalence of *P. falciparum*** compared to community-based cases. Among clinical symptoms, **headache was significantly associated with *P. falciparum* infection**, whereas no other symptoms showed strong associations. These findings suggest that age, geographic origin, and specific clinical presentations contribute to malaria transmission dynamics and severity.

Variables	Number of Samples	Total Infections	Odds ratio [95% CI]	*P. vivax*	Odds ratio [95% CI]	*P. falciparum*	Odds ratio [95% CI]	Mixed Infections	Odds ratio [95% CI]
Overall									
	1373	50.0% [687]		8.6% [118]		30.7% [421]		10.8% [148]	
Sex									
Female	59.5% [818]	58.9% [405]	1	8.9% [73]	1	29.5% [241]	1	11.1% [91]	1
Male	40.4% [555]	41.0% [282]	0.95 [0.77 to 1.18] P= 0.636	8.1% [45]	1.11 [0.75 to 1.64] P= 0.597	32.4% [180]	0.87 [0.69 to 1.09] P= 0.242	10.3% [57]	1.09 [0.77 to 1.55] P= 0.617
Age									
<5	28.8% [396]	28.5% [196]	1	5.9% [23]	1	33.2% [128]	1	11.7% [45]	1
5-15	20.5% [282]	24.6% [168]	0.67 [0.49 to 0.91] P= 0.01*	5.7% [16]	1.03 [0.53 to 1.98] P= 0.941	43.9% [124]	0.61 [0.44 to 0.83] P= 0.002**	9.9% [28]	1.16 [0.71 to 1.91] P= 0.553
>15	50.6% [695]	46.9% [322]	1.14 [0.89 to 1.53] P= 0.314	11.2% [78]	0.49 [0.30 to 0.79] P= 0.004**	24.3% [169]	1.49 [1.13 to 1.95] P= 0.004**	10.8% [75]	1.06 [0.72 to 1.57] P= 0.772
Origin									
Community	42.2% [580]	52.2% [303]	1	5.5% [32]	1	39.5% [229]	1	7.2% [42]	1
Hospital	57.7% [793]	48.4% [384]	1.16 [0.94 to 1.44] P= 0.162	10.8% [86]	0.48 [0.32 to 0.73] P= 0.001**	24.2% [192]	2.04 [1.62 to 2.58] P < 0.0001**	13.3% [106]	0.51 [0.35 to 0.74] P= 0.0004**

Symptoms								
Fever	0.3% [4]	0.29% [2]	1	25.0% [1]	1	25.0% [1]	1	0	1
Chills	0	0	1.00 [0.01 to 73.27] P= 1.000	0	0.43 [0.01 to 33.59] P= 0.703	0	0.43 [0.01 to 33.59] P= 0.703	0	0.11 [0.00 to 14.76] P = 0.378
Abdominal Pain	0.4% [5]	0.29% [2]	1.50 [0.11 to 21.31] P = 0.765	0	4.71 [0.15 to 151.49] P= 0.381	0	4.71 [0.15 to 151.49] P= 0.381	40.0% [2]	0.15 [0.01to 4.39] P= 0.275
Headache*(data missing)	0.8% [11]	0.73% [5]	1.20 [0.12 to 11.87] P= 0.876	9.1% [1]	3.33 [0.16 to 70.91] P= 0.440	9.1% [1]	3.33 [0.16 to 70.91] P= 0.440	27.3% [3]	0.27 [0.01 to 6.46] P= 0.419
Nausea	0.1% [1]	0	3.00 [0.08 to 115.35] P= 0.555	0	1.29 [0.03 to 53.52] P= 0.895	0	1.29 [0.03 to 53.52] P= 0.895	0	0.33 [0.00 to 25.41] P= 0.619
Diarrhea	0.2% [2]	0	5.00 [0.15 to 166.59] P= 0.368	0	2.14 [0.06 to 77.54] P= 0.677	0	2.14 [0.06 to 77.54] P= 0.677	0	0.56 [0.01 to 37.56] P= 0.785
Difficulty Breathing	0	0	1.00 [0.01 to 73.27] P= 1.000	0	0.43 [0.01 to 33.59] P= 0.703	0	0.43 [0.01 to 33.59] P= 0.703	0	0.11 [0.00 to 14.76] P= 0.378
Muscle Pain	0.4% [5]	0.44% [3]	0.67 [0.05 to 9.47] P= 0.765	0	4.71 [0.15 to 151.49] P= 0.381	0.20% [1]	1.33 [0.06 to 31.12] P= 0.858	40.0% [2]	0.16 [0.00 to 4.39] P= 0.275
Fatigue	0.7% [9]	0.44% [3]	2.00 [0.18 to 22.05] P= 0.571	22.2% [2]	0.67 [0.05 to 9.47] P= 0.765	0	8.14 [0.26 to 250.74] P= 0.230	11.1% [1]	0.63 [0.02 to 18.83] P= 0.789

Genetic polymorphisms of *PvDBP1* and Phylogenic Relatedness

A total of eight mutations were identified in the *PvDBP1* region II (amino acid 291-460) among 75 *Pv* isolates from Cameroon, of which two mutations showed exceptionally high frequency in the Duffy-negative populations. They included I379L observed in 74.1% and E225K in 53.7% of the samples (Figure 4A). Other less frequent mutations included N372K (27.8%), G339D (22.2%), W442C (11.1%), K234E (47.1%), K326E (7.4%), and G417V (5.6%). The four variants detected in the Cameroon *Pv* including K326E, G339D, N372K, and I379L were shared with the Thai isolates, though I379L (30%) and G339D (19%) were observed at considerably lower frequencies in Thailand (Figure 4B). Only two mutations K326E and N372K were shared between the Cameroonian and Botswana isolates. The Chinese *Pv* was most polymorphic with 13 variants in the binding region. Among them, L333F, N375D, S398T, and T404R were unique and not observed elsewhere. The remaining nine variants were overlapped with the Sudanese, Ethiopian, and Brazilian isolates. However, none of these variants were detected in the Cameroonian and Botswana *Pv*. Both the Brazilian and Sudanese/Ethiopian isolates had mutations K371E, E385K, and L424I, but only N417K was overlapped with the Cameroonian *Pv* (Figure 4B).

(A)

(B)

Country	Region	Number of Isolates	R308S	K326E	L333F	G339D	K371E	N372K	N375D	I379L	D384G	E385K	K386N/Q	R390H	S398T	T404R	N417K	L424I	W437R	W442C
Cameroon	Central Africa	75		✓		✓		✓		✓							✓			✓
Botswana	Southern Africa	12		✓				✓												
Ethiopia	East Africa	78	✓			✓						✓		✓				✓		
Sudan	East Africa	60	✓			✓			✓			✓	✓	✓			✓	✓	✓	
Brazil	South America	15				✓						✓	✓				✓	✓		
China	Southeast Asia	18	✓		✓	✓		✓		✓		✓	✓	✓	✓	✓	✓	✓	✓	
Thailand	Southeast Asia	10		✓		✓		✓		✓										

Figure 4. **Distribution of DBP Gene Mutations in *P. vivax* Isolates from Cameroon and Global Comparisons:** (**A**) The bar chart illustrates the frequency of *Plasmodium vivax* Duffy Binding Protein (DBP) gene mutations in isolates from Cameroon. The mutations E225K, K234E, K326E, G339D, N372K, I379L, G417V, and W442C were observed with varying prevalence, with I379L showing the highest frequency. Mutations marked with an asterisk (*)— K326E, G339D, N372K, and I379L—are also observed in Thailand. (**B**) Comparison of *PvDBP1* Region II mutations observed in *P. vivax* isolates from Cameroon with those reported in geographically and epidemiologically diverse regions, including Thailand and China (Asia), Brazil (South America), Sudan and Ethiopia (East Africa), and Botswana (Southern Africa). Cameroon shared four mutations (K326E, G339D, N372K, and I379L) with Thailand, though the frequencies of I379L and G339D were lower in Thai isolates. K326E and I379L were also found in Botswana. Brazilian and Sudanese/Ethiopian isolates exhibited a broader mutation profile, including several variants not found in Cameroon. Chinese isolates displayed unique mutations such as L333F, S398T, and T404R.

Phylogenetic analyses indicated distinct genetic clustering of *Pv* isolates from various geographic regions, highlighting both global diversity and regional adaptation. *Pv* populations

from Central-South Africa, South America, Asia, and East Africa were found in separate clusters

(Figure 5A), of which the African and Asian *Pv* were closely related. *Pv* from South America

formed a distinct clade separated from the other regions. When *Pv* from Africa were analyzed

alone (Figure 5B), most of the isolates from Cameroon (in red) form a distinct cluster, sister to

those from Botswana (light blue). Two other main clades were observed—one contained mostly

Ethiopian (purple) and Ugandan (orange) isolates, and another contained the Ethiopian and

Sudanese (green) isolates, indicating substantial diversity among the African *Pv*.

274
Figure 5. Global and Regional Phylogenetic Relationships of *Plasmodium vivax* Isolates.
This figure illustrates the phylogenetic relationships of *Plasmodium vivax* isolates from different
geographical regions using whole genome sequence data: (**A**) Displays a circular phylogenetic
tree that segregates *P. vivax* populations into major global regions, including Central-South
Africa, South America, Asia, and East Africa; (**B**) Presents a radial phylogenetic tree, with color-
coded branches corresponding to isolates from Cameroon (red), Botswana (light blue), Uganda
(orange), Ethiopia (purple), Sudan (green), and reference genomes (yellow). Both trees

demonstrate the genetic diversity and evolutionary divergence of *P. vivax* across different geographical populations, with significant clustering observed among isolates from specific regions. The phylogenetic structure highlights potential gene flow and regional adaptation patterns, particularly in East African populations. These insights are crucial for understanding the evolutionary history and transmission dynamics of *P. vivax* on both global and regional scales.

Discussion

Molecular assays by 18S rRNA and *PvDBP1* indicated a large number of *Pv* cases in different parts of Cameroon. These findings challenge the longstanding dogma that Duffy-negative individuals are resistant to the parasite but instead suggesting that *Pv* could be well adapted and circulating broadly in predominantly Duffy-negative Central Africa(7, 16, 18). Geographical and environmental factors play a crucial role in shaping *Pv* transmission dynamics in Africa(19). The southwest region of Cameroon, such as Buea, situated at a higher altitude on the slope of Mount Cameroon, presents favorable conditions for *Pv* development due to its relatively lower temperatures. Unlike *Pf*, which requires warmer temperatures (18°C and above) for its development in mosquito vectors, *Pv* can develop at temperatures as low as 16°C to 18°C, albeit at a slower rate(20). This unique thermal tolerance may allow *Pv* to thrive in cooler environments. High rainfall and frequent flooding in Buea and Bamenda likely contribute to higher malaria transmission compared to Bertoua(21). Recent evidence suggests that malaria is expanding its endemic range to higher altitudes, including regions such as the Ethiopian highlands(18), Kenya(19), and Colombia(21). In Ethiopia, *Pv* has spread into previously malaria-free highland areas with a mono-*Pv* infection rate of ~8%, similar to our findings. Due to socio-political unrest and large-scale migration in the English-speaking regions of Cameroon since 2016, *Pv* may have readily spread to different parts of Cameroon or beyond. Individuals aged 5–

15 years had a significantly lower risk of *Pv* than children under 5 years, suggesting partial

immunity or reduced exposure(22). The potential spread and adaptation of *Pv* emphasizes the

need to consider geographical/environmental heterogeneity when developing malaria control and

intervention strategies.

It is not surprising that hospital-based samples exhibit higher parasitemia. However,

several asymptomatic infections from the community were shown with relatively high

parasitemia that may contribute to onward transmission. In Ethiopia, *Pv* in Duffy-negative

individuals was reported in both asymptomatic volunteers from communities and febrile

patients(23, 24), and was shown with gametocytes(25). The use of microscopy and RDT

diagnostics, though convenient, could vastly misidentified or missed low-density *Pv* infections.

In this study, some individuals classified as microscopy-negative showed moderate to high

parasitemia by qPCR, raising concerns about the diagnostic sensitivity of microscopy and

PvLDH-based RDTs, especially in Duffy-negative individuals. Similar microscopy results have

been reported in Indonesia(26), where microscopy detected only 5 mixed *Pv-Pf* cases, while

nested PCR detected 346 cases across various clinical categories, including asymptomatic

individuals and those treated with antimalarials(26). Our findings indicated that PvLDH-based

RDTs may contribute to false-negative results, even in cases of high parasitemia. This could be

attributed to defective or degraded test kits, lot variability, or antigenic variation that affects the

detection capability of PvLDH in majority Duffy-negative Africans. Molecular tools like qPCR

offer superior sensitivity and specificity, particularly in detecting low-density or mixed *Pv*

infections, ensuring both symptomatic and asymptomatic carriers are identified and monitored

effectively.

The *PvDBP1* gene encodes a critical ligand that facilitates *Pv* invasion of human

erythrocytes by binding to the Duffy antigen receptor, making it a key molecular marker for both

species confirmation and evolutionary analysis. While previous studies in Cameroon have

documented the presence of *Pv*, this is the first study to utilize *PvDBP1* not only to validate *Pv*

infections in Duffy-negative individuals, but also to examine genetic variations and phylogenetic

relationships of the Cameroonian *Pv* with global populations. In the Cameroonian *Pv*, mutations

I379L and E225K occurred at high frequencies. These and several other identified mutations,

including K326E, G339D, and N372K overlapped with *Pv* populations from Southeast Asia(27).

Mutations I379L and G339D occurred at substantially higher frequencies in our dataset than

other geographical isolates, suggesting regional adaptation or selective pressures in Central

African parasite populations. Future functional assays would clarify their role in parasite

invasion and virulence.

Previous studies indicated striking similarity of the *Pv* genome between Asian and East

African parasite populations with high identity-by-descent(20). Our recent studies found no clear

genetic differentiation in *Pv* between Duffy-negatives and Duffy-positives, supporting the notion

of shared ancestry and gene flow between the two populations(16, 28). The present findings

further highlighted the genetic relatedness of the Cameroonian and Botswana *Pv* and that both

being distinct from the East African isolates. Such differentiation may reflect local adaptation of

the parasites to regional ecological and host conditions. Ecological variation, particularly in

mosquito vector dynamics, likely plays a significant role in shaping *Pv* population structure and

transmission. For example, *Plasmodium* parasites have been shown with great compatibility with

sympatric mosquito species(29). In Cameroon and Benin, *Anopheles coluzzii* was identified as a

competent vector for *Pv*(30), suggesting its potential significance in sustaining transmission in

West/Central Africa(31). By contrast, in East Africa, *An. arabiensis* and *An. funestus* are primary

vectors for malaria transmission. While *An. arabiensis* is more commonly associated with *Pf*,

there is evidence suggesting its potential role in transmitting *Pv* (32, 33)(34). Adaptation to

different mosquito vector populations may drive genetic distinctiveness between the Central and

East African *Pv*.

356   Apart from vector-parasite co-evolution, host genetic factors may also play a role in

shaping parasite population structure. Evidence of a severe population bottleneck followed by

rapid expansion in human *Pv*, along with the pseudogenization of genes such as *RBP2d*, *RBP2e*,

and *RBP3*, which remain intact in ape *Pv*, supports the notion of host-specific adaptation in

parasite populations(35). The distinct *Pv* population structures observed between East and

Central/Southern Africa may reflect differences in historical human migration and host

reservoirs. East Africa, where Duffy-positive individuals account for two-third of the general

populations and that *Pv* has been circulating for a long time in the region, likely represents a

larger, more ancestral parasite gene pool; whereas Central and Southern Africa may represent a

portion of *Pv* parasites recently introduced from East Africa that shaped by bottlenecks and the

predominance of Duffy-negative hosts(35, 36). The observed genetic relatedness between

Cameroonian and Botswanan isolates suggests possible recent gene flow. The Bantu expansion

is the most significant and well-studied migration event between Central and Southern Africa,

where Bantu-speaking people migrated from West-Central Africa, eventually settling in much of

the southern half of the continent and interacting with indigenous groups like the Khoisan,

around 3,000 to 5,000 years ago(37, 38). This migration event could have shaped the parasite

population structure.

This study has a few limitations. First, samples and related metadata were collected at a

single timepoint and thus restricts our ability to assess *Pv* transmission over time. Also, the

genetic analysis based on *PvDBP1* alone does not reflect evolutionary changes at the genome

level for *Pv* in Duffy-negative individuals. The geographic representation of African *Pv* isolates,

particularly samples from West Africa, is limited in the phylogenetic analysis. The apparent

genetic distinctiveness of Central African isolates may change with broader sampling across the

continent. Our ongoing investigations use a genome-based approach together with spatial

analyses to determine source-sink dynamics of *Pv* infections, with the goal to unravel the origin

and adaptation of *Pv* in Africa.

To conclude, the detection of several *Pv* cases in asymptomatic individuals underscores

its potential for silent transmission, emphasizing the need for enhanced surveillance in both

community and clinical settings. PvLDH-based RDTs may contribute to false-negative

diagnostic results, even in cases of high parasitemia. Molecular tools like qPCR offer superior

sensitivity and specificity, particularly in detecting low-density or mixed *Pv* in Duffy-negative

individuals. Our present findings call for tailored malaria control strategies that consider both

geographical/environmental heterogeneity and the unique features of *Pv* in Duffy-negative

populations.

Acknowledgments

We extend our sincere gratitude to Jordan Bennett for her valuable contributions in this

study. We also acknowledge the dedicated team in Cameroon for their invaluable efforts in

sample collection, processing, and logistical support. Their commitment and diligence were

essential to the successful completion of this study. Additionally, we thank our collaborators and

supporting institutions for their contributions and insights, which have significantly enriched this

research.

Funding

This research was supported by an institutional grant from Drexel University. The

funding body had no role in the study design, data collection, analysis, manuscript preparation,

or decision to publish.

Author Bio

Dynamic and results-driven postdoctoral fellow at Drexel University College of Medicine

with extensive experience in global health research, molecular diagnostics, and health

technology implementation. Demonstrated expertise in malaria genomics, vaccine efficacy

evaluation, and digital health innovation. Proven track record in managing cross-functional

teams, leading NIH-funded studies, and collaborating with international stakeholders to drive

impactful health interventions.

*Address for correspondence: Cheikh Cambel Dieng, Department of Microbiology and

Immunology, College of Medicine, Drexel University, Philadelphia 19129, Pennsylvania, USA;

email: cd3424@drexel.edu;

References

1.   Dieng CC, Gonzalez L, Pestana K, Dhikrullahi SB, Amoah LE, Afrane YA, et al.

Contrasting Asymptomatic and Drug Resistance Gene Prevalence of Plasmodium falciparum in

Ghana: Implications on Seasonal Malaria Chemoprevention. Genes (Basel). 2019 Jul 16;10(7).

2.   King CL, Adams JH, Xianli J, Grimberg BT, McHenry AM, Greenberg LJ, et al.

Fy(a)/Fy(b) antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to

Plasmodium vivax malaria. Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20113-8.

3.   Ngum NH, Fakeh NB, Lem AE, Mahamat O. Prevalence of malaria and associated

clinical manifestations and myeloperoxidase amongst populations living in different altitudes of

Mezam division, North West Region, Cameroon. Malar J. 2023 Jan 19;22(1):20.

4.   Gautret P, Legros F, Koulmann P, Rodier M, Jacquemin J-L. Imported Plasmodium

vivax malaria in France: geographical origin and report of an atypical case acquired in Central or

Western Africa. Acta tropica. 2001;78(2):177-81.

5.   Mangoni ED, Severini C, Menegon M, Romi R, Ruggiero G, Majori G. Case report: An

unusual late relapse of Plasmodium vivax malaria. American Journal of Tropical Medicine and

Hygiene. 2003;68(2):159-60.

6.   Russo G, Faggioni G, Paganotti GM, Djeunang Dongho GB, Pomponi A, De Santis R, et

al. Molecular evidence of Plasmodium vivax infection in Duffy negative symptomatic

individuals from Dschang, West Cameroon. Malar J. 2017 Feb 14;16(1):74.

7.   Djeunang Dongho GB, Gunalan K, L'Episcopia M, Paganotti GM, Menegon M,

Efeutmecheh Sangong R, et al. Plasmodium vivax Infections Detected in a Large Number of

Febrile Duffy-Negative Africans in Dschang, Cameroon. Am J Trop Med Hyg. 2021 Jan

12;104(3):987-92.

8.   Ntumngia FB, McHenry AM, Barnwell JW, Cole-Tobian J, King CL, Adams JH. Genetic

variation among Plasmodium vivax isolates adapted to non-human primates and the implication

for vaccine development. Am J Trop Med Hyg. 2009 Feb;80(2):218-27.

9.   Seraphin EH, Lagarde BJ, Richard P, Jules N, Farrick NO. Diversity, structure and health

of a cocoa based agroforest system in the Humid dense forest, East Cameroon. International

Journal of Biodiversity andConservation. 2021:165.

10.   Akenji T, Ntonifor N, Kimbi H, Abongwa E, Ching J, Anong D, et al. The epidemiology

of malaria in Bolifamba, a rural setting of Mount Cameroon: Seasonal variations in

parasitological indices of transmission [MIM-TA-141660]. ACTA TROPICA; 2005:

ELSEVIER SCIENCE BV PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS; 2005. p.

S295-S6.

11.   Fru-Cho J, Bumah VV, Safeukui I, Nkuo-Akenji T, Titanji VP, Haldar K. Molecular

typing reveals substantial Plasmodium vivax infection in asymptomatic adults in a rural area of

Cameroon. Malar J. 2014 May 3;13:170.

12.   Miguel RB, Coura JR, Samudio F, Suárez-Mutis MC. Evaluation of three different DNA

extraction methods from blood samples collected in dried filter paper in Plasmodium subpatent

infections from the Amazon region in Brazil. Rev Inst Med Trop Sao Paulo. 2013;55(3).

13.   Lo E, Yewhalaw D, Zhong D, Zemene E, Degefa T, Tushune K, et al. Molecular

epidemiology of Plasmodium vivax and Plasmodium falciparum malaria among Duffy-positive

and Duffy-negative populations in Ethiopia. Malar J. 2015 Feb 19;14:84.

14.   Abagero BR, Rama R, Obeid A, Tolossa T, Legese F, Lo E, et al. Detection of Duffy

Blood Group Genotypes and Submicroscopic Plasmodium Infections Using Molecular

Diagnostic Assays in Febrile Malaria Patients. Res Sq. 2023 Dec 6.

15.   Gunalan K, Lo E, Hostetler JB, Yewhalaw D, Mu J, Neafsey DE, et al. Role of

Plasmodium vivax Duffy-binding protein 1 in invasion of Duffy-null Africans. Proc Natl Acad

Sci U S A. 2016 May 31;113(22):6271-6.

16.   Lo E, Russo G, Pestana K, Kepple D, Abagero BR, Dongho GBD, et al. Contrasting

epidemiology and genetic variation of Plasmodium vivax infecting Duffy-negative individuals

across Africa. International Journal of Infectious Diseases. 2021;108:63-71.

17.   Ménard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbasoa A, et al.

Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people.

Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5967-71.

18.   Ketema T, Bacha K, Getahun K, Portillo HAD, Bassat Q. Plasmodium vivax

epidemiology in Ethiopia 2000-2020: A systematic review and meta-analysis. PLoS Negl Trop

Dis. 2021 Sep;15(9):e0009781.

19.   Shanks GD, Hay SI, Omumbo JA, Snow RW. Malaria in Kenya's western highlands.

Emerg Infect Dis. 2005 Sep;11(9):1425-32.

20.   Benavente ED, Manko E, Phelan J, Campos M, Nolder D, Fernandez D, et al. Distinctive

genetic structure and selection patterns in Plasmodium vivax from South Asia and East Africa.

Nat Commun. 2021 May 26;12(1):3160.

21.   Siraj AS, Santos-Vega M, Bouma MJ, Yadeta D, Ruiz Carrascal D, Pascual M.

Altitudinal changes in malaria incidence in highlands of Ethiopia and Colombia. Science. 2014

Mar 7;343(6175):1154-8.

22.   Wamae K, Wambua J, Nyangweso G, Mwambingu G, Osier F, Ndung'u F, et al.

Transmission and Age Impact the Risk of Developing Febrile Malaria in Children with

Asymptomatic Plasmodium falciparum Parasitemia. J Infect Dis. 2019 Feb 23;219(6):936-44.

23.   Bradley L, Yewhalaw D, Hemming-Schroeder E, Jeang B, Lee MC, Zemene E, et al.

Comparison of Plasmodium Vivax Infections in Duffy Negatives From Community and Health

Center Collections in Ethiopia. Res Sq. 2023 Oct 3.

24.   Bradley L, Yewhalaw D, Hemming-Schroeder E, Jeang B, Lee MC, Zemene E, et al.

Epidemiology of Plasmodium vivax in Duffy negatives and Duffy positives from community and

health centre collections in Ethiopia. Malar J. 2024 Mar 14;23(1):76.

25.   Singh K, Mukherjee P, Shakri AR, Singh A, Pandey G, Bakshi M, et al. Malaria vaccine

candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a

Phase I trial. NPJ Vaccines. 2018;3:48.

26.   Deo DA, Herningtyas EH, Intansari US, Perdana TM, Murhandarwati EH, Soesatyo M.

Difference between Microscopic and PCR Examination Result for Malaria Diagnosis and

Treatment Evaluation in Sumba Barat Daya, Indonesia. Trop Med Infect Dis. 2022 Jul 29;7(8).

27.   Tapaopong P, da Silva G, Chainarin S, Suansomjit C, Manopwisedjaroen K, Cui L, et al.

Genetic diversity and molecular evolution of Plasmodium vivax Duffy Binding Protein and

Merozoite Surface Protein-1 in northwestern Thailand. Infect Genet Evol. 2023 Sep;113:105467.

28.   Kepple D, Hubbard A, Ali MM, Abargero BR, Lopez K, Pestana K, et al. Plasmodium

vivax From Duffy-Negative and Duffy-Positive Individuals Share Similar Gene Pools in East

Africa. J Infect Dis. 2021 Oct 28;224(8):1422-31.

29.   Joy DA, Gonzalez-Ceron L, Carlton JM, Gueye A, Fay M, McCutchan TF, et al. Local

adaptation and vector-mediated population structure in Plasmodium vivax malaria. Mol Biol

Evol. 2008 Jun;25(6):1245-52.

30.   Feufack-Donfack LB, Sarah-Matio EM, Abate LM, Bouopda Tuedom AG, Ngano

Bayibéki A, Maffo Ngou C, et al. Epidemiological and entomological studies of malaria

transmission in Tibati, Adamawa region of Cameroon 6 years following the introduction of long-

lasting insecticide nets. Parasit Vectors. 2021 May 8;14(1):247.

31.   Ossè RA, Tokponnon F, Padonou GG, Glitho ME, Sidick A, Fassinou A, et al. Evidence

of Transmission of Plasmodium vivax 210 and Plasmodium vivax 247 by Anopheles gambiae

and An. coluzzii, Major Malaria Vectors in Benin/West Africa. Insects. 2023 Feb 25;14(3).

32.   Massebo F, Balkew M, Gebre-Michael T, Lindtjørn B. Entomologic inoculation rates of

Anopheles arabiensis in southwestern Ethiopia. Am J Trop Med Hyg. 2013 Sep;89(3):466-73.

33.   Eligo N, Wegayehu T, Pareyn M, Tamiru G, Lindtjørn B, Massebo F. Anopheles

arabiensis continues to be the primary vector of Plasmodium falciparum after decades of malaria

control in southwestern Ethiopia. Malar J. 2024 Jan 9;23(1):14.

34.   Ogola EO, Odero JO, Mwangangi JM, Masiga DK, Tchouassi DP. Population genetics of

Anopheles funestus, the African malaria vector, Kenya. Parasit Vectors. 2019 Jan 8;12(1):15.

35. Loy DE, Plenderleith LJ, Sundararaman SA, Liu W, Gruszczyk J, Chen YJ, et al.

Evolutionary history of human Plasmodium vivax revealed by genome-wide analyses of related

ape parasites. Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):E8450-e9.

36. Abebe A, Dieng CC, Dugassa S, Abera D, Shenkutie TT, Assefa A, et al. Genetic

differentiation of Plasmodium vivax duffy binding protein in Ethiopia and comparison with other

geographical isolates. Malar J. 2024 Feb 23;23(1):55.

37. Campbell MC, Tishkoff SA. The evolution of human genetic and phenotypic variation in

Africa. Curr Biol. 2010 Feb 23;20(4):R166-73.

38. Campbell MC, Hirbo JB, Townsend JP, Tishkoff SA. The peopling of the African

continent and the diaspora into the new world. Curr Opin Genet Dev. 2014 Dec;29:120-32.

538